Pharmaceutical companies' China revenue, Top7 announced (with list)

Pharma Network February 20, China rankings announced, the ranking of the secondary changes in the Chinese market announced recently, multinational pharmaceutical companies have announced the 2020 financial results, more than 7 enterprises announced China's results.
According to The Rubik's Cube, seven foreign pharmaceutical companies that announced China's performance will achieve a total of $21.4 billion in 2020, of which AstraZeneta continues to rank first in the Chinese market for multinational pharmaceutical companies with nearly $5.4 billion in Chinese revenue, with Merca East and Roche in second and third place respectively.
addition to Sanofi, which is subject to volume purchases, all six pharmaceutical companies achieved positive growth, with Lilly accounting for the highest increase, at 19 per cent.
(File Photo: Pharmaceutical Rubik's Cube) Star Pharmaceuticals contributed big on February 12, when British pharmaceutical giant AstraZeneta released its fourth quarter and full-year 2020 financial statements.
AstraZeneca's full-year revenue was $26,617 million, up 9 percent from a year earlier, while net income attributable was $4,752 million, compared with $616 million a year earlier, and diluted earnings per share were $2.44, compared with $1.03 a year earlier.
's full-year sales costs were $5,299 million, up 7.7 percent year-on-year, research and development spending was $5,991 million, down 1 percent year-on-year, and sales, general and management expenses were $11.294 billion, down 3 percent year-on-year.
's performance in China was brighter than its full-year total revenue.
's total revenue in China reached $5,373 million in 2020, or 20.2 percent of AstraZeneta's global revenue, according to the company's financial results.
also said that while AstraZeneta remains the world's largest multinational drug company in the Chinese market, the slowdown in growth in China (10%) has become an indisputable fact, compared with a growth rate of 35% and 28% in 2019 and 2018, due to the impact of the COVID-19 outbreak, health care negotiations and lower drug prices for volume purchases.
In recent years, AstraZeneone has aggressively disposed of its patent-period assets and focused on its core innovative pharmaceutical business, completing a shift in performance-driven upgrades, particularly its star drugs Tagrisso, Lynparza (Olapali), Imfinzi (Duvalliyu monoli), and Farxiga (Dagley Net), which have been the main drivers of AstraZeneta's earnings growth, bringing in a combined $10.1 billion.
? Pension enterprises? The fastest growth rate in 2020, Lilly with 19% growth, ranked the largest multinational enterprises, with people's hearts? Pension? The company's stereotypes are different, and this is the first time Lilly has disclosed its performance in China.
s full-year revenue was $24.54 billion, up 10 percent from a year earlier, while Q4's revenue was $7.44 billion, up 22 percent from a year earlier.
addition, Lilly's full-year sales revenue in China reached $1,117 million, up 19% year-on-year, with 309 million U.S. dollars contributed by Thyvyt, a Xinta partner.
data show that Lilly is able to grow by nearly 20 percent by 2020, thanks to Bamlanivimab's FDA emergency use authorization in November to treat patients over 12 years of age and adults with mild to moderate COVID-19, contributing $871 million. Revenue rose 50 percent with the FDA's authorization to treat hospitalized children and recognize COVID-19 patients, while the combined use of eight new drugs listed after 2014 contributed a combined $12.4 billion, accounting for more than 50 percent of the company's total revenue.
Lilly also hopes for future growth in the development of heavy-weight products: it believes that tirzepatide (GIP/GLP-1 dual-subject agonist), LOXO-305 (BTK C481S mutation inhibitor) and donanemab (N3pG-β amyloid) are heavyweight products that can significantly improve patient clinical outcomes and, if successful, support their performance over the next 10 years.
the only negative growth figures, of the seven foreign companies reporting revenue from its pharmaceutical business in China, only Sanofi's China revenue showed negative growth (-7.7 per cent).
February 5, Sanofi reported 2020 results, with net income of 36,041 million euros, down 0.2 percent from a year earlier.
of these, the pharmaceutical business earned EUR 25,674 million (-3.1%), the vaccine business revenue was EUR 5.973 billion (-8.8%), and the consumer health business revenue was EUR 4.394 billion (-1.9%).
's specific business segments are performing very differently: Dupixent's overall sales growth of up to 70 per cent in 2020 is largely due to the explosive market performance of the product, which has been an important driver of Sanofi's performance.
Addition to Dupixent, Sanofi has also shown good growth in some of its new innovations, including the PD-1 single-anti-Libtayo (cemiplimab) and Sarclisa (isatuximab), which increased by 318.1 percent, and the second CD38 single anti-drug drug to be marketed among the world's third-tier therapies for multiple myeloma in March 2020.
performance of Sanofi's mature branded drugs is not encouraging: Pluvix (Clopidogrel) and Aprovel (Ebershatan), which were previously sold in China.
Plavix China revenue fell 52 per cent to 341 million euros in 2020, while Aprovel China revenue fell 33.4 per cent to 190 million euros.
To some extent, the growth of Sanofi's Chinese market is subject to volume procurement, as a national level of the volume procurement program, four batches of implementation, the procurement list through consistent evaluation of domestic generic drugs with the lowest price or standard reduction, the corresponding product regulations multinational enterprises over-patented high-priced drugs to achieve clinical replacement, the current annual report from multinational pharmaceutical companies, this operation has been effective.
For multinational pharmaceutical companies, the path to divesting out-of-date patented original drug assets and focusing on innovative drugs has become clear, and next, Cypress Blue will continue to pay attention to the strategic adjustment of multinational pharmaceutical companies in China.